drugset
drugset / Trial / NCT05567510

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

NCT05567510 ↗

Phase 1 Completed 8 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess mass balance, biotransformation, and excretion of BMS-986369 following study drug administration.

Timeline

Start
2022-10-20
Primary completion
2022-12-27
Completion
2022-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Golcadomide Other / unclassified — —

Indications

No indication recorded.